c-mos Immunoreactivity Aids in the Diagnosis of Gestational Trophoblastic Lesions

International Journal of Gynecological Pathology

Volumn 23, Issue 2, 2004, Pages 145-150

  Xue, Wei Cheng ^a   Khoo, Ui Soon ^b   Ngan, Hextan Y S ^b   Chan, Kelvin Y K ^b   Ip, Philip P C ^b   Tsao, Sai Wah ^b   Cheung, Annie N Y ^b  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

C mos; Choriocarcinoma; Germ cell tumor; Gestational trophoblastic disease; Gynecological neoplasm; Hydatidiform mole

Indexed keywords

ANTIBODY; ANTIBODY P 19; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ARTICLE; CHORIOCARCINOMA; CHORION; CHORION TYPE INTERMEDIATE TROPHOBLAST; CHORION VILLUS; CYTOTROPHOBLAST; DIFFERENTIAL DIAGNOSIS; EMBRYONAL CARCINOMA; ENDOMETRIUM CARCINOMA; ENDOMETRIUM SARCOMA; FEMALE; FEMALE GENITAL TRACT TUMOR; GERM CELL TUMOR; GYNECOLOGIC DISEASE; HUMAN; HUMAN TISSUE; HYDATIDIFORM MOLE; IMMATURE TERATOMA; IMMUNOHISTOCHEMISTRY; IMPLANTATION SITE INTERMEDIATE TROPHOBLAST; LEIOMYOBLASTOMA; LEIOMYOSARCOMA; LOW GRADE ENDOMETRIUM SARCOMA; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PERITONEUM TUMOR; PRIMARY PERITONEUM PAPILLARY SEROUS CARCINOMA; PRIORITY JOURNAL; PROTO ONCOGENE; PROTO ONCOGENE C MOS; SQUAMOUS CELL CARCINOMA; SYNCYTIOTROPHOBLAST; TERATOMA; TROPHOBLASTIC DISEASE; TROPHOBLASTIC TUMOR; UTERINE CERVIX CARCINOMA; VILLOUS CYTOTROPHOBLAST; VILLOUS INTERMEDIATE TROPHOBLAST; YOLK SAC TUMOR;

DIAGNOSIS, DIFFERENTIAL; FEMALE; GENITAL NEOPLASMS, FEMALE; GESTATIONAL TROPHOBLASTIC NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; PLACENTA; PREGNANCY; PROTO-ONCOGENE PROTEINS C-MOS; TUMOR MARKERS, BIOLOGICAL;

EID: 1642271865     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-200404000-00009     Document Type: Article

References (29)

1. Sagata N, Watanabe N, Vande Woude GF, et al. The c-mos proto-oncogene product is a cytostatic factor responsible for meiotic arrest in vertebrate eggs. Nature 1989;342:512-8.
2. Sagata N. What does Mos do in oocytes and somatic cells? Bioessays 1997;19:13-21.
3. Wang XM, Yew N, Peloquin JG, et al. Mos oncogene product associates with kinetochores in mammalian somatic cells and disrupts mitotic progression. Proc Natl Acad Sci U S A 1994;91: 8329-33.
4. Fukasawa K, Rulong S, Resau J, et al. Overexpression of mos oncogene product in Swiss 3T3 cells induces apoptosis preferentially during S-phase. Oncogene 1995;10:1-8.
5. Ling YH, Yang Y, Tomos C, et al. Paclitaxel-induced apoptosis is associated with expression and activation of c-Mos gene product in human ovarian carcinoma SKOV3 cells. Cancer Res 1998;58: 3633-40.
6. Kurata N, Akiyama H, Taniyama T, et al. Dose-dependent regulation of macrophage differentiation by mos mRNA in a human monocytic cell line. EMBO J 1989;8:457-63.
7. Lenormand JL, Benayoun B, Guillier M, et al. Mos activates myogenic differentiation by promoting heterodimerization of MyoD and E12 proteins. Mol Cell Biol 1997;17:584-93.
8. Fukasawa K, Vande Woude GF. Mos overexpression in Swiss 3T3 cells induces meiotic-like alterations of the mitotic spindle. Proc Natl Acad Sci U S A 1995;92:3430-4.
9. Fukasawa K, Vande Woude GF. Synergy between the Mos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability. Mol Cell Biol 1997; 17:506-18.
10. Leonard JH, Kearsley JH, Chenevix-Trench G, et al. Analysis of gene amplification in head-and-neck squamous-cell carcinoma. Int J Cancer 1991;48:511-5.
11. Gerharz CD, Ramp U, Olert J, et al. Cytomorphological, cytogenetic, and molecular biological characterization of four new human renal carcinoma cell lines of the clear cell type. Virchows Arch 1994;424:403-9.
12. Li CC, Chen E, O'Connell CD, et al. Detection of c-mos proto-oncogene expression in human cells. Oncogene 1993;8:1685-91.
13. Xerri L, Charpin C, Hassoun J, et al. Mos oncogene expression in human ovarian tumors. Anticancer Res 1991;11:1629-34.
14. Shuin T, Misaki H, Kubota Y, et al. Differential expression of proto-oncogenes in human germ cell tumors of the testis. Cancer 1994;73:1721-7.
15. de Foy KA, Gayther SA, Colledge WH, et al. Mutation analysis of the c-mos proto-oncogene in human ovarian teratomas. Br J Cancer 1998;77:1642-4.
16. Eng C, Foster KA, Healey CS, et al. Mutation analysis of the c-mos proto-oncogene and the endothelin-B receptor gene in medullary thyroid carcinoma and phaeochromocytoma. Br J Cancer 1996; 74:339-41.
17. Athanasiou A, Gorgoulis VG, Zacharatos P, et al. c-mos immunoreactivity is an indicator of good prognosis in lung cancer. Histopathology 2000;37:45-54.
18. Perunovic B, Athanasiou A, Quilty RD, et al. Expression of mos in astrocytic tumors and its potential role in neoplastic progression. Hum Pathol 2002;33:703-7.
19. Park JS, Namkoong SE, Lee HY, et al. Expression and amplification of cellular oncogenes in human developing placenta and neoplastic trophoblastic tissue. Asia Oceania J Obstet Gynaecol 1992; 18:57-64.
20. Shih IM, Seidman JD, Kurman RJ. Placental site nodule and characterization of distinctive types of intermediate trophoblast. Hum Pathol 1999;30:687-94.
21. Shih IM, Mazur MT, Kurman RJ. Gestational trophoblastic disease and related lesions. In: Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract. 5th ed. New York: Springer-Verlag, 2002:1193-224.
22. Paradinas FJ, Elston CW. Gestational trophoblastic diseases. In: Fox H, Wells M, eds. Haines & Taylor Obstetrical and Gynaecological Pathology. 5th ed. Edinburgh: Churchill Livingstone, 2003:1359-430.
23. Singer G, Kurman RJ, McMaster MT, et al. HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis. Am J Surg Pathol 2002;26:914-20.
24. Shih IM, Kurman RJ. Expression of melanoma cell adhesion molecule in intermediate trophoblast. Lab Invest 1996;75:377-88.
25. Cheung ANY, Srivastava G, Chung LP, et al. Expression of the p53 gene in trophoblastic cells in hydatidiform moles and normal human placentas. J Reprod Med 1994;39:223-7.
26. Cheung ANY, Srivastava G, Pittaluga S, et al. Expression of c-myc and c-fms oncogenes in trophoblastic cells in hydatidiform mole and normal human placenta. J Clin Pathol 1993;46:204-7.
27. Cheung ANY, Shen DH, Khoo US, et al. p21WAF1/CIP1 expression in gestational trophoblastic disease: correlation with clinico-pathological parameters, and Ki67 and p53 gene expression. J Clin Pathol 1998;51:159-62.
28. Wong SY, Ngan HY, Chan CC, et al. Apoptosis in gestational trophoblastic disease is correlated with clinical outcome and Bcl-2 expression but not Bax expression. Mod Pathol 1999;12:1025-33.
29. Yew N, Strobel M, Vande Woude GF. Mos and the cell cycle: the molecular basis of the transformed phenotype. Curr Opin Genet Dev 1993;3:19-25.